Neoadjuvant Chemotherapy of Nimotuzumab Plus Nab-Paclitaxel in Squamous Cell Carcinoma of Esophagus
Status:
Withdrawn
Trial end date:
2017-01-01
Target enrollment:
Participant gender:
Summary
Nimotuzumab, a humanized monoclonal antibody against epidermal growth factor receptor
(EGFR),has been shown to be effective and safe in some studies with head-neck
cancers.Nab-paclitaxel regimen in advanced NSCLC has a better tumor response rate and safety
than solvent-based paclitaxel.However,the safety and efficacy of Nimotuzumab plus
nab-paclitaxel regimen is uncertain in neoadjuvant therapy in esophageal cancer.The
investigators then initiated a phase II clinical trial with Nimotuzumab plus
Nab-paclitaxel/cisplatin as the neoadjuvant chemotherapy in patients with locally advanced
esophageal squamous cell carcinoma to observe the efficacy and safety of the combination.